In Stock Cell Lines
Mus musculus (Mouse)
Embryo
Adherent
The Fbxl12 Knockout NIH 3T3 Cell Line is a CRISPR/Cas9-edited loss-of-function model derived from mouse embryonic fibroblasts. It targets the Fbxl12 gene, which encodes a substrate recognition subunit of the SCF E3 ubiquitin ligase complex. Fbxl12 mediates ubiquitination and proteasomal degradation of Cyclin D1, a key regulator of the G1/S cell cycle transition. Disruption of this gene enables studies on cell cycle control and the ubiquitin-proteasome system. The NIH 3T3 host cells are immortalized fibroblasts widely used for investigating ECM production, cell adhesion, and proliferation. This knockout cell line is particularly valuable for research into cancer cell cycle dysregulation, ubiquitin-dependent proteolysis, and inhibitor screening, utilizing techniques such as flow cytometry, western blotting, and proliferation assays.
AFAP1 Knockout K562 Polyclonal Cells
Cat. No. ARG20024
FPGT Knockout HT29 Polyclonal Cells
Cat. No. ARG13841
CSNK1D Knockout Jurkat Polyclonal Cells
Cat. No. ARG13248
ABHD12 Knockout A2780 Polyclonal Cells
Cat. No. ARG28538
IFI16 Knockout NCI-H1299 Polyclonal Cells
Cat. No. ARG30791
CALR Knockout Hela Polyclonal Cells
Cat. No. ARG41894
The Fbxl12 Knockout NIH 3T3 Cell Line is a CRISPR/Cas9-edited knockout cell line in which the murine Fbxl12 gene has been disrupted to establish a loss-of-function model for investigating its role in cell cycle regulation. Fbxl12 encodes the F-box and leucine-rich repeat protein 12, a substrate recognition component of the SCF (Skp1-Cullin1-F-box) E3 ubiquitin ligase complex. By mediating the ubiquitination and subsequent proteasomal degradation of key cell cycle regulators, Fbxl12 controls the G1/S transition, making this knockout line a strategic tool for dissecting ubiquitin-dependent cell cycle control.
The host NIH 3T3 cell line is a well-characterized, immortalized mouse embryonic fibroblast line derived from Mus musculus. These fibroblasts are widely utilized in biomedical research for their roles in extracellular matrix (ECM) production, tissue repair, and cell adhesion. The NIH 3T3 line provides a robust and reproducible cellular background for studying fundamental processes such as proliferation, adhesion, and signal transduction. Its fibroblast identity positions it as an ideal model for exploring the interplay between cell cycle progression and fibroblast-specific functions.
Mechanistically, Fbxl12 functions within the SCF complex by interacting with Skp1, Cullin1, and Rbx1, and recruiting an E2 ubiquitin-conjugating enzyme to target proteins for polyubiquitination. A primary downstream target is Cyclin D1, whose ubiquitin-mediated proteasomal degradation is critical for proper G1/S cell cycle transition. Disruption of Fbxl12 therefore leads to impaired ubiquitination and stabilization of Cyclin D1, potentially causing dysregulated cell cycle entry. This pathway lies at the intersection of cell cycle regulation and the ubiquitin-proteasome system, with implications for cancer biology where aberrant Cyclin D1 levels often drive tumorigenesis.
The biological relevance of Fbxl12 deletion in NIH 3T3 fibroblasts is underscored by the cell line??s intrinsic properties. NIH 3T3 cells are frequently used to model oncogenic transformation and investigate the molecular events governing growth factor signaling and cycle progression. In this context, Fbxl12 knockout disrupts a critical regulatory node controlling Cyclin D1 turnover, offering researchers a means to examine how the SCF complex influences fibroblast proliferation, ECM remodeling, and adhesion dynamics. This model thus bridges the gap between fundamental cell cycle research and cancer-relevant fibroblast biology.
This knockout cell line is suited for a wide spectrum of experimental applications. It enables detailed investigation of the ubiquitin-proteasome system, high-throughput screening for cell cycle inhibitors, and functional studies on cancer cell proliferation. Typical assays include western blotting for Cyclin D1 to assess protein stability, flow cytometry for cell cycle distribution analysis, MTT or BrdU proliferation assays, and ubiquitination assays to monitor substrate modification. Researchers can also explore proteasome inhibition responses or evaluate SCF complex integrity via co-immunoprecipitation. For additional information or to request validation data, please contact Ascent Research.